2548 research outputs found
Sort by
Comparison of Anti-TNF Therapy on the Development of Psoriasiform Skin Lesions in Patients with IBD
No full text
Post-Anesthesia Cognitive Outcomes in Propofol vs. Ketamine Sedation for Colonoscopy: A Retrospective Cohort Study
Get PDF
Artificial Intelligence Applications in Cardio-Oncology: A Comprehensive Review.
No full textPURPOSE OF REVIEW: This review explores the role of artificial intelligence (AI) in cardio-oncology, focusing on its latest application across problems in diagnosis, prognosis, risk stratification, and management of cardiovascular (CV) complications in cancer patients. It also highlights multi-omics analysis, explainable AI, and real-time decision-making, while addressing challenges like data heterogeneity and ethical concerns.
RECENT FINDINGS: AI can advance cardio-oncology by leveraging imaging, electronic health records (EHRs), electrocardiograms (ECG), and multi-omics data for early cardiotoxicity detection, stratification and long-term risk prediction. Novel AI-ECG models and imaging techniques improve diagnostic accuracy, while multi-omics analysis identifies biomarkers for personalized treatment. However, significant barriers, including data heterogeneity, lack of transparency, and regulatory challenges, hinder widespread adoption. AI significantly enhances early detection and intervention in cardio-oncology. Future efforts should address the impact of AI technologies on clinical outcomes, and ethical challenges, to enable broader clinical adoption and improve patient care
Series Multiblood Pump Design With Dual Activation for Pediatric Patients With Heart Failure.
No full textThe translational development of pediatric ventricular assist devices (VADs) lags years behind adult device options, negatively impacting pediatric patient outcomes. To address this need, we are developing a novel, series-flow, double-blood pump VAD that integrates an axial and centrifugal pump into a single device. The axial pump is used for initial circulatory assistance in younger patients; then, an internal activation mechanism triggers the centrifugal pump to activate in line with the axial pump, providing additional pressure and flow to match pediatric patient growth cycles. Here, we focused on the design and improvement of the device flow paths through computational analysis and in vitro hydraulic testing of a prototype. We estimated pressure-flow generation, fluid scalar stresses, and blood damage levels. In vitro hydraulic tests correlated well with shear stress transport (SST) predictions, with an average deviation of 4.5% for the complex, combined flow path. All data followed expected pump performance trends. The device exceeded target levels for blood damage in the blade tip clearances, and this must be both investigated and addressed in the next design phase. These study findings establish a strong foundation for the future development of the Drexel Double-Dragon VAD
Methylphenidate-Induced Dyskinesia in a 47-Year-Old Female With Acute Lymphoblastic Leukemia.
No full textDyskinesia describes a broad category of involuntary body movements. The presentation of dyskinesia is variable, ranging from quick jerking and twitching to smooth dance-like movements. Dyskinesia can occur in the extremities, face, or trunk. They can result from the use of certain medications and various medical conditions. One cause, explored in this paper, is dyskinesia as a side effect of methylphenidate use. We report on a 47-year-old woman with a past medical history of hypoplastic low-grade myelodysplastic syndrome with pancytopenia, acute lymphoblastic leukemia (in remission), and generalized fatigue treated with methylphenidate for her fatigue and decreased concentration. The patient presented from home to the emergency department with expressive aphasia, facial spasming, and involuntary extremity movement. Initial concern for stroke was ruled out and ultimately methylphenidate was determined to be the offending agent. Although our case focuses on an adult, cancer patient affected by dyskinesia following methylphenidate use, dyskinesia is a reported side effect with methylphenidate use in other populations. Clinicians should be aware of this association because of methylphenidate\u27s extensive use in the treatment of attention deficit hyperactivity disorder (ADHD) and its increasing use in other patient populations, like cancer patients and patients with brain injuries